Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA

Traders Union
All News
Companies
Cullinan data for CLN-978 in SLE

Top Stories

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Anastasiia Chabaniuk

06.06.2026

Cullinan Therapeutics presents initial clinical data for CLN-978 in refractory SLE and RA — Cullinan data for CLN-978 in SLE

Cullinan Therapeutics has unveiled initial clinical data for CLN-978, an investigational CD19xCD3 T cell engager, targeting patients with refractory systemic lupus erythematosus (SLE) and difficult-to-treat rheumatoid arthritis (RA) at the EULAR2026 conference.

The findings, shared in a poster presentation, mark a step forward for the development of potential therapies for patients with limited treatment options for these autoimmune diseases. Full details of the study and its implications remain closely monitored by the medical and investment communities.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Cullinan Therapeutics has previously pursued T cell engager therapies targeting B cells to address underlying mechanisms of autoimmune diseases, according to an earlier report on the company's experimental focus. In June, Cullinan said it would present early clinical data on CD19 and BCMA T cell engagers for autoimmune conditions at a scheduled meeting. These developments come as the company expands its pipeline in challenging autoimmune indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

How to build wealth from scratch in 3 practical steps

By Johnathan Maverick
14 hours ago

How to build wealth from scratch in 3 practical steps

Editors' Picks

Kospi Index crash: Why South Korean market fell alongside AI stocks

By Eugene Komchuk
16 hours ago

Kospi Index crash: Why South Korean market fell alongside AI stocks

Editors' Picks

Bitcoin or Ferrari: Which investment is better?

By Mira Kyivska
Yesterday

Bitcoin or Ferrari: Which investment is better?

Editors' Picks

All Editors' Top Picks

Latest Cullinan News

Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments

By Eugene Komchuk
03.06.2026

Cullinan Therapeutics explores B cell depletion in novel autoimmune treatments

Companies

Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers

By Dmytro Kharkov
26.05.2026

Cullinan Therapeutics to unveil initial clinical data on CD19 and BCMA T cell engagers

Companies

Cullinan Therapeutics unveils key financial results and outlines upcoming development milestones

By Mikhail Vnuchkov
07.05.2026

Cullinan Therapeutics unveils key financial results and outlines upcoming development milestones

Companies

All Cullinan News

Johnathan Maverick
14 hours ago

How to build wealth from scratch in 3 practical steps

Eugene Komchuk
16 hours ago

Kospi Index crash: Why South Korean market fell alongside AI stocks

Mira Kyivska
Yesterday

Bitcoin or Ferrari: Which investment is better?

Mira Kyivska
06.06.2026

Strategy sells Bitcoin: Small sale tests market confidence

Mikhail Vnuchkov
05.06.2026

Ledger vs. Trezor: Search for ideal crypto wallet

Ivan Andriyenko
3 min ago

U.S. stocks fall after early gains on geopolitical concerns, Mario Nawfal notes

Yaroslav Dmytrenko
8 min ago

Jason Pizzino: Seeks details on Strategy average Bitcoin buy price

Elena Nikulina
18 min ago

Industrial was considered teflon in CRE a year ago, Danielle DiMartino Booth notes

Andrey Mastykin
18 min ago

Nominal growth has remained stable for over two years without inventories and trade, Eric Basmajian notes

Hanna Syniavska
34 min ago

Preston Byrne: Encourages creation of new token for rapid wealth

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Eugene Komchuk
9 hours ago

Sam Bankman-Fried formally seeks pardon from Trump

Sam Bankman-Fried formally seeks pardon from Trump

Ivan Andriyenko
12 hours ago

Hayes dumps WLD days after Maelstrom's bullish call

Hayes dumps WLD days after Maelstrom's bullish call

Hanna Syniavska
15 hours ago

Powell warns Trump pressure on Fed could threaten markets

Powell warns Trump pressure on Fed could threaten markets

Igor Krasulya
16 hours ago

Nvidia bets on South Korea in AI infrastructure race

Nvidia bets on South Korea in AI infrastructure race

Olga Shendetskaya
17 hours ago

Oil rises above $97 after new Israel-Iran exchange of strikes

Oil rises above $97 after new Israel-Iran exchange of strikes

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Alphabet decline intensifies amid record AI investment

Anton Kharitonov
Now

Microsoft declines amid AI expectation reset, but fundamentals remain strong

Dmytro Kharkov
Now

Snowflake tests post-earnings breakout as AI rally faces first challenge

Anton Kharitonov
Now

Apple under pressure as investor skepticism grows

Dmytro Kharkov
Now

Nvidia tests key support as Jensen Huang calls AI sell-off a buying opportunity

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.